Boston Scientific Schedule of Major Presentations at Transcatheter
Cardiovascular Therapies 2012
NATICK, Mass., Oct. 18, 2012 /PRNewswire/ -- Boston
Scientific Corporation (NYSE: BSX) is scheduled to present
sponsored research at the 24th Annual Transcatheter Cardiovascular
Therapeutics (TCT) scientific symposium, sponsored by the
Cardiovascular Research Foundation, which takes place October 22 – 26 in Miami, Florida. The clinical
presentations will provide new insights on Boston Scientific
research in coronary and peripheral artery disease, including
aortic valve disease and atrial fibrillation.
Schedule of Events
All programs are Eastern Daylight
Time, with events held at the Miami
Beach Convention Center unless otherwise indicated.
Tuesday, October 23
- Contemporary CTO PCI Symposium: BridgePoint Medical and the
Hybrid Approach: Join BridgePoint Medical, Boston
Scientific and co-chairs J. Aaron
Grantham, M.D., and Craig A.
Thompson, M.D., MMSc for breakfast at 6:30 a.m.
Presentations that will follow from 7:00
a.m. to 8:00 a.m. include: Hybrid Aglorithm: U.S. and EU
Training/Proctoring Experience; Angiographic Evaluation and
Procedural Approach, and two case study presentations followed by
discussion and a question and answer session. The event will
include expert faculty Dimitri Karmpaliotis, M.D., Simon Walsh, M.D., MRCP, and James Spratt, BSc, M.D., and is scheduled to
occur in Room C227-228.
- Two-Year Long Lesion Results from the PLATINUM Trial:
Paul S. Teirstein, M.D., will
present in poster format two-year outcomes following implantation
of 32mm and 38mm PROMUS Element™ Everolimus-Eluting Platinum
Chromium Coronary Stent System. All posters to be presented
from 8:00 a.m. to 10:00 a.m. in Hall
D.
- Pre-Clinical Findings to support the SYNERGY™
Everolimus-Eluting Platinum Chromium Coronary Stent System: The
SYNERGY Stent features an ultra-thin everolimus-eluting
bioabsorbable polymer coating in which the polymer and drug
dissipate by three months. The following presentations will
be given in poster format between 8:00 a.m.
and 10:00 a.m. in Hall D:
- Armando Tellez, M.D.:
Abluminal Coated Everolimus-Eluting Coronary Stent Provides
an Anti-inflammatory Vascular Effect Compared to Bare Metal
Stent
- Greg Wilson, M.D.: Porcine
Vascular Compatibility and Polymer Safety Study
- REPRISE I: Ian T.
Meredith, M.B.B.S., Ph.D., will present results from the
feasibility study of the Repositionable Lotus™ Aortic Valve
Replacement: Three-Month Outcomes in 11 Patients at High Surgical
Risk. The Lotus Aortic Valve System is the first
transcatheter aortic valve replacement (TAVR) device of its kind
that is designed to minimize aortic regurgitation (leaking) and be
both fully repositionable and retrievable prior to release.
The study will be presented in Room D240-241 at 12:15 p.m.
- Findings from the "ASA Plavix Registry" (ASAP):
Horst Sievert, M.D., Ph.D., will
present 14-month data results of the WATCHMAN® Left
Atrial Appendage Closure (LAAC) Device in Patients with Atrial
Fibrillation and Contraindications to Oral Anticoagulation.
Data to be presented at 11:00
a.m. in Room D235-236.
- PROTECT AF: Saibal Kar, M.D., to present a
Sub-Analysis of the PROTECT AF Study; evaluating the long term
effects of the WATCHMAN LAAC Device versus long term warfarin
therapy in patients with atrial fibrillation older than 75 years of
age. Data to be presented at 11:15
a.m. in Room D235-236.
- ORION Trial Poster Presentation: Dan Clair, M.D., to present 12-month results on
the study of the Epic Vascular Stent System for the treatment of
iliac artery disease. Poster to be presented from
8:00 a.m. to 10:00 a.m. in Hall
D.
Wednesday, October 24
- The Future of Stents, TAVR, LAAC and Renal Denervation
Symposium: Boston Scientific will host a case-based
review of what it calls "technologies that transform tomorrow and
products that perform today," co-moderated by Ted Feldman, M.D., and Jeffery Moses M.D., in The Perry South Beach
Hotel ballroom, from 7:00 p.m. to 8:30 p.m. The presenters
and their topics are:
- Dean Kereiakes, M.D.:
Drug-Eluting Stent Advancements
- Ian T. Meredith, M.B.B.S.,
Ph.D.: Transcatheter Aortic Valve Replacement
- Maurice Buchbinder, M.D.:
Left Atrial Appendage Closure
- Krishna Rocha-Singh, M.D.:
Renal Denervation for Resistant Hypertension
The Boston Scientific Technology Showcase will immediately
follow from 8:30 p.m. to 10:00 p.m.
Conference attendees are invited to view "technologies that
transform tomorrow and products that perform today" from Boston
Scientific at booth 272 in the main exhibit hall.
The WATCHMAN, SYNERGY and Lotus devices are investigational
devices and not available for sale in the
United States.
About Boston Scientific
Boston Scientific is a
worldwide developer, manufacturer and marketer of medical devices
that are used in a broad range of interventional medical
specialties. For more information, please visit:
www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of
1934. Forward-looking statements may be identified by words
like "anticipate," "expect," "project," "believe," "plan,"
"estimate," "intend" and similar words. These forward-looking
statements are based on our beliefs, assumptions and estimates
using information available to us at the time and are not intended
to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding clinical trials and outcomes, our technology, product
performance and importance, and competitive offerings. If our
underlying assumptions turn out to be incorrect, or if certain
risks or uncertainties materialize, actual results could vary
materially from the expectations and projections expressed or
implied by our forward-looking statements. These factors, in
some cases, have affected and in the future (together with other
factors) could affect our ability to implement our business
strategy and may cause actual results to differ materially from
those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place
undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions; and
future business decisions made by us and our competitors. All
of these factors are difficult or impossible to predict accurately
and many of them are beyond our control. For a further list
and description of these and other important risks and
uncertainties that may affect our future operations, see Part I,
Item 1A – Risk Factors in our most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission, which
we may update in Part II, Item 1A – Risk Factors in
Quarterly Reports on Form 10-Q we have filed or will file
hereafter. We disclaim any intention or obligation to
publicly update or revise any forward-looking statements to reflect
any change in our expectations or in events, conditions or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary
statement is applicable to all forward-looking statements contained
in this document.
|
|
CONTACT:
|
Steven
Campanini
|
|
508-652-5740 (office)
|
|
214-546-5034 (cell, during TCT)
|
|
Media
Relations
|
|
Boston
Scientific Corporation
|
|
steven.campanini@bsci.com
|
|
|
|
Michael
Campbell
|
|
508-650-8023 (office)
|
|
Investor
Relations
|
|
Boston
Scientific Corporation
|
|
investor_relations@bsci.com
|
SOURCE Boston Scientific Corporation